Welcome to our dedicated page for Henry Schein SEC filings (Ticker: HSIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Henry Schein, Inc. (NASDAQ: HSIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a FORTUNE 500 and S&P 500® health care solutions company listed on the Nasdaq Global Select Market, Henry Schein uses its filings to report financial results, governance changes, and other material events relevant to shareholders and analysts.
Henry Schein’s current reports on Form 8-K offer timely updates on topics such as quarterly and year-to-date financial performance, leadership transitions, and key corporate announcements. For example, recent 8-K filings have furnished press releases reporting financial results for specific quarters and have disclosed changes in senior leadership, including the planned retirement of the Chief Executive Officer from that role and related succession planning.
In addition to 8-Ks, investors typically look to Henry Schein’s annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. These periodic reports, referenced in company news releases, contain discussions of operations, financial condition, risk factors, and litigation matters, as well as commentary on strategic initiatives and partnerships such as the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P.
Stock Titan enhances these filings with AI-powered summaries that help explain complex disclosures in clear language. Instead of reading entire documents, users can review concise explanations of key points, including segment performance, risk factor highlights, and notable changes in capital allocation or governance. Real-time updates from the EDGAR system mean that new Henry Schein filings, such as 8-Ks reporting financial results or leadership changes, appear promptly on this page.
For those tracking insider activity and executive arrangements, Form 4 and 8-K disclosures relating to departures, appointments, and compensatory arrangements provide additional context on management and board-level decisions. By combining raw filings with AI-generated insights, this page helps investors, researchers, and health care market participants interpret Henry Schein’s regulatory reporting more efficiently.
Henry Schein Inc. director Philip A. Laskawy sold shares of the company. On March 5, 2026, he completed an open-market sale of 2,844 shares of common stock at a price of $80.36 per share. After this transaction, he directly owned 21,961 shares of Henry Schein common stock.
HSIC submitted a Form 144 notice relating to proposed sales of Common stock. The filing lists two tranches tied to restricted stock vesting: 556 shares dated 03/03/2024 and 4,739 shares dated 03/03/2025. The filing names Fidelity Brokerage Services LLC as the broker and shows a filing date of 03/04/2026.
Henry Schein Inc. reported that CEO Frederick M. Lowery acquired a sign-on equity-based award of 30,723 shares of common stock in the form of restricted stock units under the company’s 2024 Stock Incentive Plan. The RSUs vest in three equal annual installments, contingent on his continued service.
Henry Schein SVP & Chief Financial Officer Ronald N. South reported two stock dispositions on February 27, 2026. He disposed of 6,815 shares of common stock in a transaction coded as a disposition to the issuer and separately disposed of 709 shares at $82.39 per share to satisfy tax withholding obligations tied to the vesting of a March 1, 2023 performance-based restricted stock/unit grant. Following these transactions, he directly holds 73,850 shares of Henry Schein common stock.
Henry Schein Inc. senior vice president and chief human resources officer Christine Zayac Sheehy reported two share dispositions on common stock. She disposed of 780 shares to the company and a further 88 shares at $82.39 per share to satisfy tax withholding tied to the vesting of a March 1, 2023 performance-based restricted stock/unit grant. Following these transactions, she directly holds 11,830 shares of Henry Schein common stock.
Henry Schein Inc. executive Thomas C. Popeck, CEO of Henry Schein Products, reported dispositions of company stock on February 27, 2026. He disposed of a total of 1,339 shares, leaving him with 34,918 shares of common stock held directly after the transactions.
The filing shows an issuer disposition of 1,202 shares at a price of $0.00 per share. It also records a separate tax-withholding disposition of 137 shares at $82.39 per share. According to the footnote, those 137 shares were surrendered to Henry Schein to satisfy Popeck’s tax withholding obligation upon vesting of his March 1, 2023 grant of performance-based restricted stock/units, which vested on the preceding business day because March 1, 2026 was a non-business day.
Henry Schein Inc. executive Mark E. Mlotek reported share dispositions in company stock. On February 27, 2026, he disposed of 9,440 shares of common stock in a disposition to the issuer and a further 1,065 shares at $82.39 per share to cover tax withholding on vested performance-based restricted stock/units.
After these transactions, his direct holdings totaled 86,479 shares, which include shares held in joint tenancy with his spouse. He also reported indirect holdings of 5,916 equivalent shares as trustee of family trusts and 4,085 equivalent shares through a 401(k) plan stock fund.
Henry Schein’s EVP & Chief Operating Officer Michael S. Ettinger reported dispositions of company stock tied to equity award vesting, rather than open-market sales. On February 27, 2026, he disposed of 9,047 shares of common stock back to the issuer and an additional 914 shares at $82.39 per share to satisfy tax withholding obligations on his March 1, 2023 performance-based restricted stock/unit grant, according to the footnotes. After these transactions, he directly held 91,661 shares and had an indirect interest in the equivalent of 210 shares through the Henry Schein 401(k) Savings Plan’s unitized stock fund.
Henry Schein Inc. director and Chairman/CEO Stanley M. Bergman reported several stock transactions involving Henry Schein common shares. On March 2, 2026, entities associated with his spouse sold a total of 43,812 shares in open-market transactions at a weighted average price of about $81.31 per share. On February 27, 2026, he disposed of 48,531 shares directly back to the company and surrendered 7,349 shares to cover tax withholding upon vesting of a prior performance-based restricted stock/units grant, and he also reported 9,832 equivalent shares held through the company’s 401(k) plan.